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Applications of nanotechnology for melanoma treatment, diagnosis, and
theranostics
Abstract

Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage
melanoma can be surgically removed, with a survival rate of 99%. However, metastasized melanoma is difficult
to cure. The 5-year survival rates for patients with metastasized melanoma are still below 20%. Metastasized
melanoma is currently treated by chemotherapy, targeted therapy, immunotherapy and radiotherapy. The
outcome of most of the current therapies is far from optimistic. Although melanoma patients with a mutation
in the oncogene v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) have an initially higher positive
response rate to targeted therapy, the majority develop acquired drug resistance after 6 months of the therapy.
To increase treatment efficacy, early diagnosis, more potent pharmacological agents, and more effective
delivery systems are urgently needed. Nanotechnology has been extensively studied for melanoma treatment
and diagnosis, to decrease drug resistance, increase therapeutic efficacy, and reduce side effects. In this review,
we summarize the recent progress on the development of various nanoparticles for melanoma treatment and
diagnosis. Several common nanoparticles, including liposome, polymersomes, dendrimers, carbon-based
nanoparticles, and human albumin, have been used to deliver chemotherapeutic agents, and small interfering
ribonucleic acids (siRNAs) against signaling molecules have also been tested for the treatment of melanoma.
Indeed, several nanoparticle-delivered drugs have been approved by the US Food and Drug Administration
and are currently in clinical trials. The application of nanoparticles could produce side effects, which will need
to be reduced so that nanoparticle-delivered drugs can be safely applied in the clinical setting.
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Abstract: Melanoma is the most aggressive type of skin cancer and has very high rates of
mortality. An early stage melanoma can be surgically removed, with a survival rate of 99%.
However, metastasized melanoma is difficult to cure. The 5-year survival rates for patients
with metastasized melanoma are still below 20%. Metastasized melanoma is currently
treated by chemotherapy, targeted therapy, immunotherapy and radiotherapy. The outcome
of most of the current therapies is far from optimistic. Although melanoma patients with a
mutation in the oncogene v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) have
an initially higher positive response rate to targeted therapy, the majority develop acquired
drug resistance after 6 months of the therapy. To increase treatment efficacy, early diagnosis,
more potent pharmacological agents, and more effective delivery systems are urgently
needed. Nanotechnology has been extensively studied for melanoma treatment and diagnosis,
to decrease drug resistance, increase therapeutic efficacy, and reduce side effects. In this
review, we summarize the recent progress on the development of various nanoparticles for
melanoma treatment and diagnosis. Several common nanoparticles, including liposome,
polymersomes, dendrimers, carbon-based nanoparticles, and human albumin, have been used
to deliver chemotherapeutic agents, and small interfering ribonucleic acids (siRNAs) against
signaling molecules have also been tested for the treatment of melanoma. Indeed, several
nanoparticle-delivered drugs have been approved by the US Food and Drug Administration
and are currently in clinical trials. The application of nanoparticles could produce side effects,
which will need to be reduced so that nanoparticle-delivered drugs can be safely applied in
the clinical setting.
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Melanoma, originated from melanocytes, is the most aggressive type of skin cancer.1,2
Although melanoma represents only a very small proportion of skin cancer incidence,
it accounts for the vast majority of skin cancer deaths.3 For example, there were more
than 2 million new cases of skin cancer in USA in 2012, and among them only 75,000
(3.75%) cases were melanoma.4 However, melanoma accounts for 9000 (75%) deaths
among the total 12,000 deaths caused by skin cancer in 2012. An early-stage melanoma
that has not spread or metastasized to other organs can be removed by surgery, with high
survival rates. It has been reported that the cure rate for those patients with removable
melanoma reached 97%−99.8% after chemosurgery.5 However, metastasized irremovable
melanoma needs to be treated by other standard therapies, such as chemotherapy,
radiotherapy, targeted therapy, and immunotherapy.6,7 Unfortunately, treatment outcomes
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are not satisfactory and patients’ responses to most of these
therapies are very poor.8
At present, the most common drug used for the treatment
of melanoma is dacarbazine (DTIC), which is a US Food and
Drug Administration (FDA)-approved, first-line treatment
for patients with wild-type melanomas.9 Although in vitro
experiments showed that DTIC produced cytotoxicity in
many melanoma cell lines, the response to DTIC was only
5%−10% when used alone.10 The use of targeted therapy
against mutated oncogene v-Raf murine sarcoma viral
oncogene homolog B1 (BRAF) showed a dramatically
increased response, reaching 80%. 11,12 Unfortunately,
most patients will have acquired drug resistance to BRAF
inhibitors after 6 months of treatment, resulting in loss of
clinical efficacy. The median survival time of patients with
metastasized melanoma is only 6−10 months, and the 5-year
survival rate is less than 20%.13−15 Therefore, improved
treatment efficiency is urgently needed for melanoma. To
achieve this, improvement in the diagnosis and treatment is
required. Early detection of melanoma can lead to surgical
removal before metastasis. Identification of the involved
gene mutations and understanding of the dysregulation in the
key signaling pathways can help in the design of proper
therapeutic regimes. Successful treatment will also rely on
the discovery of specific, more potent pharmacological agents
and efficient delivery systems.
Nanotechnology involves the design, development,
characterization, and application of materials in nanoscale
and has been extensively studied for medical applications.16
Applications of nanotechnology in the diagnosis and
treatment of melanoma have been studied extensively
and have advanced the study of melanoma in several
aspects.17,18 Nanoparticles provide an effective drug delivery
system, allowing anticancer drugs to reach the cancer site
specifically and thus greatly improving treatment efficacy.
Nanotechnology also has helped in diagnosis, by allowing
imaging agents to be packed into nanoparticles that reach
the cancer. In this review, we summarize the recent progress
in the application of nanotechnology in the diagnosis and
treatment of melanoma.

Common nanoparticles used
in melanoma treatment
Rapid progress in understanding the biology of cancer cells
has been made in the past decade. However, the treatment
outcomes of cancers have not changed much. The failure
of anticancer therapies is considered to be due to the side
effects of most anticancer drugs, low concentrations of
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the drugs at the tumor site, and the development of drug
resistance.19,20 Nanoparticles have been studied extensively
for drug delivery, to increase anticancer treatment efficacy.
Compared with conventional drug delivery approaches,
nanoparticle-mediated delivery of anticancer drugs brings
several remarkable advantages. First, drugs delivered by
nanoparticles may have a longer biological life, due to
packaging protection, and may be concentrated in the
site of cancer due to enhanced permeability and retention
(EPR) at cancer sites.21 EPR is caused by the leakiness of
tumor vasculature as well as poor lymphatic drainage.22
Therefore, nanotechnology increases treatment efficacy
and decreases side effects. For example, Doxil® (Janssen
Biotech, Horsham, PA, USA), which is doxorubicin (Dox)
formulated in liposomes containing polyethylene glycol
(PEG), has a 100-fold longer circulation half-life and
sevenfold lower cardiocytotoxicity than has free Dox.22
Second, a nanoparticle can contain multiple drugs and
thus will facilitate combination therapy. It is known that
the combination of chemotherapy with immunotherapy or
targeted therapy produces much more effective treatment
outcomes.16 Third, nanoparticles can protect drugs made
of fragile small interfering ribonucleic acid (siRNA) or
proteins, from biochemical degradation in the human body.
This is due to the stealth-like features of nanoparticles.23
Fourth, nanoparticles produce a constant release of delivered
drugs. Furthermore, nanoparticles can be designed to have
multiple functions, such as targeting to cancer cells and
producing image contrast.24 Many nanoparticles have been
studied for the treatment of melanoma, including liposomes,
dendrimers, polymersomes, carbon-based nanoparticles,
inorganic nanoparticles, and protein-based nanoparticles
(Table 1).16,25,26
A liposome is a sphere consisting of a lipid bilayer that
contains aqueous core for hydrophilic drugs.24 Hydrophobic
drugs can be contained between the two layers. Liposome was
invented more than 50 years ago and was the first nanoparticle
used in medicine.27 Liposome is prepared by sonicating a
lipid, with a process involving emulsification. Homogeneous
nanosized liposomes can be achieved by filtering through a
0.2 µM membrane.28 Furthermore specific ligands against
tumor antigens can be attached to the liposome surface so
that the nanoparticles can target cancer cells specifically.29,30
Liposomes have been used to carry chemotherapeutic drugs,
immunocytokines, and siRNA, to increase treatment efficacy
for melanoma.16 Similar structural nanoparticles have been
designed, such as the cubosome and niosome, which consist
of lipids.24
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Table 1 Characteristics and side effects of common nanoparticles used in the study of melanoma treatment
Nanoparticle

Sample drugs delivered
for melanoma

Clinical use

Characteristics

Side effects

Possible solutions

Liposomes

Cisplatin
Vincristine
Doxorubicin

Doxil

High biocompatibility
High biodegradability
High cell uptake rates
Low drug encapsulation
efficacy
High cost
High stability
High solubility
High drug encapsulation
Uniform size
Low biodegradation
High biodegradability
Controlled release
Not uniform size
High biocompatibility
High photostability
Small size
Not biodegradable
High solubility
High stability
Low toxicity

Hand-foot syndrome (skin
rash, swelling, redness, pain)

Increase drug loading
to reduce liposomes
to be used
Use of natural lipids

Dendrimers

Polymersomes

Carbon-based
nanoparticles

Human albumin

Doxorubicin
Cisplatin
Paclitaxel
Vincristine

Not yet
available

Doxorubicin
Paclitaxel
Cyclodextrin
Doxorubicin

Not yet
available

Paclitaxel

Not yet
available

Nab-paclitaxel
(Abraxane®)

Toxicity to normal cells
due to positive charge
Surface charge

Attach anionic polymer

Accumulation in kidney
and reticuloendothelium

Control the size

Accumulation in kidney
and reticuloendothelium

Control the size

Inflammation

Adjust the size

ROS production
Side effects related with
delivered drugs

Reduce dosage for a
specific drug through
combination therapies

Abbreviations: nab-paclitaxel, nanoparticle albumin bound-paclitaxel; ROS, reactive oxygen species.

Dendrimers are synthetic polymers with branches that
form a tree-like structure, which encapsulate drugs within
their internal cavities.31 Recently, tecto(dendrimers) have been
made, which introduce covalent linkages between dendrimer
building blocks to achieve higher architectural structures.32
Schilrreff et al made a dendrimer by using amine-terminated
polyamidoamine (PAMAM) generation 5 (G5) as a core and
carboxyl-terminated PAMAM G2.5 as the shell and demonstrated it was toxic to the melanoma cell line SK-Mel-28,
but not to normal keratinocytes.32 The immunogenicity of
dendrimers may cause unwanted systemic immune reaction,
which may limit their therapeutic application.
Polymersomes are composed of amphiphilic block
copolymers, such as polylactic acid and poly(ε-caprolactone),
formulated to become nanoparticles.33 Polymersomes can
encapsulate either hydrophilic or hydrophobic drugs.34 They
are more stable and less permeable to small water-soluble
molecules than are liposomes.35 Their surface can also be
attached with ligands for targeting cells and controllable
release. Polymersomes have been used to deliver Dox for
treating melanoma and demonstrated to be preferentially
taken up by melanoma cells.36 The nanoparticles markedly
reduced tumor growth in a melanoma xenograft model.
Carbon-based nanoparticles were first made in 1985
and known as fullerenes, which were composed of
60 carbon atoms. 37 In 1991, a carbon nanotube was

International Journal of Nanomedicine 2013:8

established. Recently, nanodiamonds were used to deliver
drugs against melanoma.16 Carbon-based nanoparticles have
been shown to increase the efficacy of chemotherapy in
melanoma cells.16,38 Chaudhuri et al38 showed that a singlewalled carbon nanotube loaded with Dox induced melanoma
cell death in a dose-dependent fashion in vitro and abrogated
tumor growth in a xenograft melanoma model.
Inorganic nanoparticles made from materials such as
silica and aluminum have also been applied in melanoma
therapy. Silica can be made multiporous (which is then
called mesoporous silica) to carry more drugs than as a
simple sphere.39 A layered double hydroxide nanoparticle
is made by layering a hydroxyl (-OH) group on inorganic
materials, to carry drugs.40 This has been shown to increase
immune response to a deoxyribonucleic acid (DNA) vaccine
in a melanoma mouse model.41 At present, the capability of
layered double hydroxide to carry enough small molecular
drug is still a major problem.
Human albumin has also been used to make nanoparticles
for the treatment of melanoma. 42 An albumin-based
nanoparticle, Abraxane® (Abraxis Bioscience, Summit, NJ,
USA) (also known as ABI-007 or nanoparticle albumin
bound [nab]-paclitaxel [PTX]) has been approved by the
FDA for clinical use. PTX is non−water soluble, and nonionic
surfactant, such as Cremophor® EL (BASF Corp), is used to
make a suspension.43 This increases side effects, including
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acute hypersensitivity reactions, anemia, and cardiovascular
events.43 Albumin has been used to conjugate PTX with
Cremophor, to reduce these side effects. Clinical trials have
shown that Abraxane was better tolerated and more effective
against melanoma than was free PTX.44,45 However, a recent
report showed that poly(gamma-L-glutamylglutamine)-PTX
was more effective in reducing the growth of xenografted
B16 melanoma cells than was Abraxane and had less side
effects.46

The applications of nanotechnology
in the conventional therapies
of melanoma
Nanotechnology has been applied to most conventional
therapies for melanoma. It has been demonstrated that the
nanodelivery of drugs for chemotherapy, targeted therapy,
immunotherapy, and photodynamic therapy has greatly
increased treatment efficacy.16,25,26

Chemotherapy
Chemotherapy is the most common conventional therapy
for melanoma. Chemotherapeutic agents kill both malignant
and normal cells that are in division.47 Therefore, they
are very toxic, and this limits the dosage to be used. The
common chemotherapeutic agents used in melanoma are
DTIC, vinblastine, and temozolomide. The response rates,
however, are very low. It has been reported that the response
to DTIC, vinblastine, and temozolomide was 7%, 9.5%,
and 28%, respectively in a clinical trial with 64 patients.7
Nanoparticles have been used to deliver chemotherapeutic
agents and demonstrated to increase treatment efficacy and
reduce side effects. Zhang et al showed that delivering the
chemotherapeutic agent Dox by gold nanoparticles was very
effective against a melanoma cell line.48 Lo Prete et al applied
a cholesterol-rich nanoemulsion (termed “LDE”) to deliver
etoposide in a mouse model of melanoma.49 It decreased side
effects, increasing maximum tolerated dose fivefold, and
increased the inhibition of tumor growth by concentrating
etoposide at the tumor site (a fourfold higher concentration
in tumor than with free etoposide). Ndinguri et al packed Dox
in a nanoparticle with additional antibody against CD44, to
specifically target malignant cells.50 The nanoparticle reduced
the tumor size by 60% compared with untreated tumor.
Nab-PTX (Abraxane) has been approved by the FDA for
the treatment of breast cancer. Hersh et al reported a Phase II
clinical trial using nab-PTX (Abraxane) in both previously
treated and untreated melanoma patients.45 The response
rates were 2.7% and 21.6%, respectively. In the study,
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22% chemotherapy-naive patients discontinued treatment
due to grade 3 or 4 neuropathy, alopecia, neutropenia, and
fatigue. Kottschade et al51 conducted a Phase II clinical trial
using nab-PTX and carboplatin in advanced melanoma, in
41 chemotherapy-naive and 35 previously-treated melanoma
patients. The response rate was 25.6% in the chemotherapynaive cohort and was 8.8% in the previously-treated cohort.
The severe side effects were neutropenia, thrombocytopenia,
neurosensory problems, fatigue, nausea, and vomiting. In
another clinical trial, Kottschade et al52 showed vascular
endothelial growth factor (VEGF) antibody increased the
effect of nab-PTX. Ott et al showed that the combination of
a B cell lymphoma protein (Bcl)-2 antisense oligonucleotide,
temozolomide, and nab-PTX produced a response of 40.6%.53
Similar side effects to that revealed in Kottschade et al’s study
were also reported.

Targeted therapy
Intracellular signaling pathways play a key role in the
carcinogenesis and prognosis of many cancers, including
melanoma, and many inhibitors have been developed for the
treatment of cancer (Table 2).54,55 These pathways are activated
either by genetic defects or environmental factors.56 Obesity
is a common disease that is characterized by dysregulated
energy balance and metabolic disturbance.57 It can increase
cancer incidence and results in poorer prognosis through the
activation of multiple signal pathways, including mitogenactivated protein kinase (MAPK), phosphoinositide 3-kinase
(PI3K), and signal transducer and activator of transcription
3 (STAT3).54,58−60 The MAPK pathway is a major pathway
in melanoma. It has been studied extensively in melanoma, and
Table 2 Common inhibitors of the pMAPK and PI3K/Akt
pathways
Signaling
molecule

Inhibitors

References

RTK
Ras

Imatinib, dasatinib, sorafenib
Tipifarnib, R115777, BMS-214662,
L-778123
Sorafenib, PLX4032, XL281, RAF-265
AZD6244, U0126, PD0325901, CI-1040,
XL518, AZD8330, ARRY-162, ARRY-300,
perifosine, erucyl-phosphocholine
DHMEQ
Ly294002, Bez235, PI103
Rapamycin, Bez235, PI103
Curcumin, plumbagin

Inamdar55
Inamdar55

Raf
Mek

ERK
Akt
mTOR
NF-kB

Inamdar55
Chen54
Inamdar55
Inamdar55
Inamdar54,55
Inamdar54,55
Inamdar55

Abbreviations: Akt, protein kinase B; ERK, extracellular signal-regulated kinase; MEK,
mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; NF-kB,
nuclear factor-kappaB; PI3K, phosphoinositide 3-kinase; pMAPK, phosphorylated
mitogen-activated protein kinase; Raf, rapidly accelerated fibrosarcoma; Ras, rat
sarcoma protein (subfamily of small GTPases); RTK, receptor tyrosine kinase.

International Journal of Nanomedicine 2013:8

Dovepress

Nanotechnology for melanoma treatment, diagnosis, and theranostics

many inhibitors have been developed to inhibit this pathway
for treatment. Activation of the MAPK pathway in melanoma
has been shown to be caused by the activation of mutations
in its components; the mutation rate is 50%−70% for BRAF,
15%−30% for NRAS, 2% for KRAS and 1% for HRAS.61−63
The PI3K/protein kinase B (Akt) pathway can synergistically
affect the MAPK pathway to promote the development of
melanoma.64 The signaling pathways of MAPK and PI3K/
Akt and their crosstalk are shown in Figure 1. Both pathways
regulate a broad range of target proteins.58,65 A common
survival pathway downstream of both MAPK and PI3K/Akt
is the mitochondrial apoptosis signal pathway that includes
the Bcl-2 family of proteins, including both proapoptotic
and antiapoptotic signals. Furthermore, inhibition of both
the MAPK and PI3K/Akt pathways has been shown to have
a synergistic effect in the treatment of melanoma.66
Nanotechnology has been used to deliver certain inhibitors
of the MAPK pathway.55,67 A chitosan nanoparticle was used
to deliver the downstream target protein VEGF siRNA and
was demonstrated to improve the therapeutic effect.68 Yin et al

used functional graphene oxide to deliver a plasmid-based
STAT3 siRNA and showed significantly reduced xenografted
tumor growth.69 Indeed, STAT3 is considered as a key mediator
in melanoma which promotes brain metastasis.70 Inhibition of
phosphorylated STAT3 has been shown to increase efficacy
of tumor necrosis factor (TNF)-alpha for melanoma.71
A nanoparticle has also been designed to carry siRNA against
the oncogene c-Myc to target melanoma cells B16F10 and
demonstrated effectiveness against melanoma.72 Tran et al
prepared a nanoparticle to contain both siRNAs against BRAF
and Akt3 which markedly increased the anticancer effect.73

Targeting the mitochondrial pathway
As discussed above, a major downstream mediator of PI3K/
Akt and MAPK is the mitochondrial apoptotic pathway.
The pathway is regulated by proapoptotic proteins and
antiapoptotic proteins. The former includes Bak, Bax, Bid,
Bim, Bcl-associated death promoter (BAD), Noxa, and
PUMA. The latter includes Bcl-2, Bcl-xL, Bcl-w, Mcl-1,
and A1.74 Both PI3 K and MAPK can increase antiapoptotic

Ras

PI3K
BRAF
PIP2

PIP3

MEK

PDK

Akt
ERK1/2

NFkB

VEGF

Bcl-2
Bcl-XL
Mitochondria

mTORC1

MNK1/2
MSK1/2
RSK

PPAR
ELK1

STAT3

ETS

Figure 1 Signaling pathways in melanoma.
Notes: Oncoprotein Ras activates both the MAPK and PI3K/Akt survival pathways. Ras can stimulate BRAF activity, which in turn, activates MEK and ERK1/2. Ras also
activates PI3K, which catalyzes PIP2 into PIP3. PIP3 increases Akt activity via PDK. Both Akt and ERK1/2 act on the mitochondrial apoptosis signaling pathway and mTORC1.
Akt also targets VEGF and NF-kB. ERK1/2 can also activate STAT3 and other transcriptional factors, such as MNK1/2, MSK1/2, ELK, ETS, RSK, PPAR, ELK1, and ETS.
Abbreviations: Akt, protein kinase B; Bcl-2, B cell lymphoma protein 2; Bcl-XL, B cell lymphoma protein extra large; BRAF, v-Raf murine sarcoma viral oncogene homolog
B1; ELK1, member of the E-twenty-six transcriptional family; ERK, extracellular signal-regulated kinase; ETS, E-twenty-six (transcriptional family); MAPK, mitogen-activated
protein kinase; MEK, MAPK kinase; MNK1, 2, MAPK-interacting kinases 1, 2; MSK1, 2, stress-activated kinases 1, 2; mTORC1, mammalian target of rapamycin complex 1;
NF-kB, nuclear factor-kappaB; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; PDK, putative
3-phosphoinositide-dependent kinase; PPAR, peroxisome-proliferator-activated receptor; Ras, rat sarcoma protein (subfamily of small GTPases); RSK, 90-kDa ribosomal S6
protein kinase; STAT3, signal transducer and activator of transcription 3; VEGF, vascular endothelial growth factor.
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protein expression and decrease proapoptotic protein
expression and thus increase the ratio of antiapoptotic
proteins/proapoptotic proteins. This plays a key role in
melanoma initiation, maintenance, and drug resistance.75
Reversal of this ratio, either by inhibition of antiapoptotic
proteins or overexpressing proapoptotic proteins, has been
used for the treatment of melanoma. For example, inhibition
of Bcl-2 by ABT-737 caused melanoma cell apoptosis.76
Nanotechnology has been found to increase the therapeutic
effect of Bcl-2 inhibition. In nude mice, oblimersen
(an antisense oligonucleotide against Bcl-2) decreased
xenografted melanoma growth.77 The dual application of
oblimersen with DTIC in patients in a Phase III clinical trial
resulted in increased effectiveness compared with DTIC
alone (9 vs 7.8 months, respectively, for overall survival; 2.6
vs 1.6 months, respectively, for progression-free survival;
13.5% vs 7.5%, respectively, for overall response; 2.8%
vs 0.8%, respectively, for complete response; and 7.3% vs
3.6%, respectively for durable response).78 A nanoparticle
was made to carry Bcl-2 siRNA (as well as Myc and VEGF)
for the treatment of melanoma.79 It was shown that this
resulted in Bcl-2 reduction in both messenger ribonucleic
acid (mRNA) and protein levels. This increased anticancer
effects both in vitro and in vivo. Oblimersen has been used
in Phase I clinical trial in combination with temozolomide
and nab-PTX and proved more effective in patients with
advanced melanoma.53

folate, and further mixed with IL-2 plasmid. It was shown
that the particle inhibited tumor growth and prolonged the
survival of the melanoma-bearing mice.87 He et al used a
biodegradable polymer, poly(polycaprolactone), to make a
nanoporous miniature device for local delivery of cytokine
IFN-alpha and showed constant slow release of IFN-alpha.88
Speiser et al prepared a nanoparticle containing cytosinephosphodiester-guanine (CpG)-loaded virus-like particle
carrying melanoma antigen recognized by T cells 1 (Mart-1)
to target melanoma cells, and this nanoparticle produced
a strong immune response against melanoma, including
increased cytotoxic CD8 T-cell responses.89 Furthermore, two
ligands have been loaded into a nanoparticle. For example a
nanoparticle with both CD40 and Toll-like receptor (TLR)
stimulators was used to increase dendritic cells (DCs) and
CD8-T-cells.90 A nanoparticle combining TLR 7 and 9
ligands has also been demonstrated to exert a synergistic
effect.91 A nanoparticle made from lipopolyplexes was used
to deliver melanoma antigen mRNA. A mannosylated form
of nanoparticle has been shown to increase the efficacy of
transfection into DCs.86 In an animal model, mannosylated
and histidylated lipopolyplexes showed a greater ability to
reduce tumor growth than did the sugar-free form. A possible
explanation is that these nanoparticles can be better taken up
by DCs and thus induced more tumor-specific cytotoxic T
lymphocytes. Therefore, it is clear that nanotechnology can
be used to improve immunotherapy in melanoma.

Immunotherapy

Photodynamic therapy (PDT)

Immunotherapy is used to improve the immune response of
patients with melanoma, to increase the clearance of cancer
cells, especially those already damaged by chemotherapy or
targeted therapy. Without immunotherapy to clear damaged
cancer cells, the efficacy of treatment would not be achieved,
as these damaged cells may self-repair and become more
malignant. In melanoma, several immunocytokines have been
shown to have initial effects, but these effects are limited
by side effects.80 The commonly used immunostimulators
in melanoma are interleukin (IL)-2, interferon (IFN)-alpha,
ipilimumab, and thymosin alpha 1.81−84 IL-2 has been reported
to increase remission time but that high-dose IL-2 may cause
acute side effects and possibly death.80,83
Nanoparticles have been used to deliver immunotherapy
drugs, to reduce side effects.85,86 Yao et al prepared a novel
nanoparticle containing IL-2 and tested it in a mouse
model with xenografted melanoma.87 The nanoparticle was
made from low−molecular weight polyethylenimine (600
Da), which was linked to β-cyclodextrin, conjugated with

PDT is a therapy that applies nontoxic, light-sensitive
compounds, which become toxic after light exposure.92
In PDT, a photosensitizer is administered and then excited by
suitable irradiation, emitted from a light source, to generate
single oxygen (¹O2), superoxide anion radical (O2−), and
hydroxyl radical (OH) for therapy.92 It has been demonstrated
in a mouse model with xenografted melanoma that PDT
induced significant apoptosis, necrosis, and tumor growth
arrest and thus prolonged the survival time of the animals
bearing melanoma.92
Camerin et al used nanoparticles to carry Zn[II]phthalocyanine disulfide (C11Pc) to test PDT treatment
efficacy in a mouse model of xenograft melanoma.93 It was
found that gold nanoparticle−associated C11Pc had more
effective treatment outcomes. The nanoparticle had greater
accumulation than did free C11Pc, and the ratio of C11Pc
between melanoma and skin increased from 2.3 to 5.5.
Electron microscopy showed that the C11Pc delivered by
nanoparticles caused more damage in blood capillaries and
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endothelial cells than did the free C11Pc.93 In other work,
a nanoparticle was used to deliver two photosensitizers, to
increase therapeutic efficacy in melanoma.94

Magnetite nanoparticles
Sato et al designed a magnetite nanoparticle by conjugating
N-propionyl-cysteaminylphenol with magnetite and used this
in a B16F1 xenograft mouse model.95 Electron microscopy
demonstrated this particle appeared only in melanoma
cells. It was shown that the melanoma cells were degraded
after the application of an external alternating magnetic
field to increase the temperature in the tumor to 43°C. The
nanoparticle had a 1.7 to 5.4-fold greater effect than did the
magnetite used alone. A recent study showed that curcumin
further increased the efficacy of magnetite nanoparticles.96

Inhibition of the drug detoxification
system
The accumulation of anticancer drugs in cancer cells is
closely associated with anticancer effects. Drug resistance
is often caused by activation of the cellular detoxification
system, which includes the drug pump, permeability
glycoprotein (P-gp), and the drug metabolism enzyme,
cytochrome P450 (CYP). 97,98 Both P-gp and CYP are
regulated by several nuclear receptors, such as pregnane X
receptor (PXR), farnesoid X receptor (FXR), and constitutive
androstane receptor (CAR). Nanoparticle-delivered Dox or
PTX has been shown to inhibit P-gp expression and has a
much greater effect against melanoma that does free Dox
and PTX.99 Further, siRNA against the mRNAs for these
proteins has been carried by nanoparticles for the treatment
of cancers. It has been shown in breast cancer that the
inhibition of P-gp by nanoparticle-delivered Bcl-2, Myc,
and PXR siRNAs produced a greater anticancer effect than
did the inhibition of Bcl-2, Myc, and PXR by free siRNA.100
However, this has not been studied in melanoma and may
warrant investigation.

The application of nanotechnology
for the diagnosis of melanoma
The aim of initial diagnosis is to make a judgment about
whether melanoma is present and at what developmental
stage is the melanoma. An early diagnosis is critical to
obtain high survival rates for melanoma patients. Beyond
naked-eye examination and histological observation, many
new technologies have been used to aid diagnosis, such as
dermoscopy, total body photography, reflectance confocal
microscopy, multispectral digital imaging analysis, and
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RNA microarray.101,102 In metastasized melanoma, molecular
signatures of the melanoma may be identified so that a
proper treatment regime can be made. This is important, as
the molecular alterations are associated with intracellular
signaling pathway changes, clinical features, and responses
to different treatment regimes. Molecular diagnosis could
be included in the routine diagnosis for melanoma in the
near future.103 More and more newly developed techniques
are used in the molecular diagnosis of melanoma, such as
tissue array, proteomics, and DNA sequencing.104 During the
treatment of melanoma, judgment of efficacy is needed to
assess whether the approach used is appropriate and whether
there is any better way to increase the patient’s response to
treatment. This determination includes imaging tumor size
and vascular structure. Nanotechnology has been proven to
be a valuable tool to improve the diagnosis of melanoma.
Nanoparticle quantum dots (QDs) have been used for
the early detection of melanoma, due to their photophysical
properties, including exceptional brightness, size-tunable
emission wavelength, broad excitation spectrum with narrow
emission profile, and excellent photostability.105,106 QDs can
be conjugated with cancer-specific molecules, such as folic
acid or antibodies recognizing antigens overexpressed in
cancer cells.107 Zheng et al used PEG-COOH capped highly
fluorescent CdSe/ZnS core/shell QDs conjugated with
antibody against CD146 to detect CD146 overexpressed
melanoma cells in cultured and fixed cells.108 Flow cytometry
and confocal microscopy showed the positive cells to have
high brightness, photostability, and specificity. Kim et al
developed a coculture system containing both melanoma
cells and normal melanocytes to test QDs conjugated with
antibodies (ab732 or Ab733) against melanoma.106 It was
shown that melanoma cells could be distinguished from
melanocytes.
Melanoma is a heterogeneous disease.109 Each type may
have different mechanisms with different gene mutations
and the activation of different signaling pathways and
thus, different responses to anticancer drugs. Therefore,
it is necessary, for efficient treatment, to identify the
molecular signatures for each melanoma patient, and to plan
personalized treatment.110 For example, melanoma can be
classified into one of two categories depending on whether
a BRAF mutation exists, as the BRAF inhibitor vemurafenib
is only effective for those with a BRAF mutation. Patients
with the BRAF mutation have as high as an 80% response to
vemurafenib.111,112 Therefore, detection of a BRAF mutation
is of importance for the selection of treatment regimes.
Nanotechnology has been used to improve the detection of
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BRAF mutation.113 In an assay using microcantilever arrays,
a BRAF-specific oligonucleotide probe was used to detect
mutated BRAF. The probe was able to detect mutated BRAF
at the concentration of 500 pM but normal BRAF at a 50-fold
higher concentration. As the total RNA needed for the assay
is only 20 ng/µL, no polymerase chain reaction (PCR) was
needed for the assay.
Dendrimers have been used for monitoring metastasized
melanoma. A recent study attempted to make a dendrimer
decorated with arginine-glycine-aspartic acid and fluorescence.114 It was expected that the nanoparticle would accumulate in the tumor and then be viewed through fluorescence or
nuclear magnetic resonance (NMR) spectroscopy so that the
tumor size and vascular structure could be detected. However,
it was found that the particles accumulated in the kidney
and reticuloendothelial system. Further study is needed to
achieve the goal of using dendrimers for the diagnosis of
metastasized melanoma.

Theranostic nanomedicine in
melanoma
Recently, theranostic nanomedicine has been developed, which
uses nanoparticles for both diagnosis and treatment.115,116
By employing the capacity of nanoparticles to deliver
multiple agents in a single nanoparticle, imaging agents are
incorporated into the nanoparticles so that the action of the
therapeutic agents can be monitored in a real-time fashion.
This could help to assess drug distribution and release or to
evaluate drug response and efficacy. The information can also
be useful for researchers, to guide the formulation of new
nanoparticles with desired distribution characteristics. At
present the most commonly used nanoparticles for theranostic
purpose are liposomes and polymersomes. Imaging agents for
magnetic resonance imaging (MRI), radionuclide imaging,
and fluorescence imaging have been studied.
Theranostic nanomedicine has already been applied
in melanoma study. 117 Vannucci et al constructed a
nanoparticle based on the heavy chain of the human protein
ferritin to test in melanoma.42 The nanoparticle was loaded
with α-melanocyte stimulating hormone to specifically
target melanoma, coated with PEG molecules to prevent
binding to its physiological receptors, and loaded with the
fluorescent reagent rhodamine for the purpose of imaging.
The nanoparticle was demonstrated by confocal microscopy
to bind specifically to melanoma cells rather than to colon
cancer cells. For nanotheranostics, Ma et al used a lipid-based
nanomicelle to deliver docetaxel.118 A fluorescent dye DiR
(1,1′-dioctadecyl-3,3,3′,3′-tetramethyl indotricarbocyanine
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iodide) was coated on the hydrophobic core of micelles to
detect the distribution of the nanoparticle. The formulation
of these imaging agents as nanoparticles has facilitated
the examination of their distribution in tumor cells and
pharmacokinetic profiling. Further studies are warrant to
enable their use for clinical application.

The application of nanotechnology
in the establishment of metastasis
models
Metastasis is the main reason for death due to cancer.
Therefore, it is necessary to understand the biology of
melanoma metastasis in order to provide better approaches
for its treatment. It has been recognized that metastasis is
not a passive process.119−121 Cancer cells need to undergo
many alterations to pass barriers, such as anoikis, to reach
destination and colonization. The process of metastasis
is complicated by the control of intracellular signaling
pathways. 122 Understanding the process will facilitate
treatment to stop the metastasis. In melanoma, the most
common metastatic sites are brain, liver, lung, bone, and the
gastrointestinal tract.123 Brain metastasis is one of the major
reasons for melanoma-caused deaths because the blood−brain
barrier reduces treatment efficacy. An animal model has
been established to mimic the metastasis of melanoma to
the brain, and nanotechnology has been used to improve
the model.123
At present, the model is made by injecting melanoma
cells directly into the left cardiac ventricle to bring the cells
to brain.124 The model has been used to study the role of
growth factor−induced signaling pathways in metastasis, and
treatment efficacy.70,71,124 However, these models are not well
established, and reproducibility is poor. Nanotechnology has
been used to track the injected cells.125 Melanoma cells were
labeled with superparamagnetic iron oxide nanoparticles
and visualized by MRI. This technique contributes to the
establishment of a reproducible and predictable metastasis
model and could be useful for the prediction of therapeutic
outcomes.

Future directions
Acquired drug resistance to BRAF-inhibitors is a major
issue in the treatment of melanoma. For example, the initial
response to vemurafenib is 80%, but the majority of patients
will develop drug resistance. The mechanisms for such
resistance could be diverse, including the overexpression of
P-gp, increased drug metabolism, enhanced self-repairing
ability, altered drug targets, and the activation of intracellular
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signaling pathways.126 The use of nanotechnology in dealing
with this issue could be helpful but is still challenging. So far,
not many studies have been done to employ nanotechnology
to overcome drug resistance. Khdair et al created a single
multidrug nanoparticle with both chemotherapeutic and
PDT agents that would target melanoma cells, in order
to overcome acquired drug resistance.127 Tran et al used a
nanoparticle with both sorafenib and ceramide to prevent
acquired drug resistance.128 However, the mechanisms for
acquired drug resistance in melanoma have been shown to
be diverse. The use of different drugs in nanoparticles will
be needed depending on the mechanisms of acquired drug
resistance.
Evaluation and the avoidance of severe side effects caused
by nanoparticles could be critical for the successful clinical
application of nanoparticles for drug delivery. Cytotoxicity
to normal cells in relation to nanoparticles could be caused
by size-related toxicity and the leaching of components.129
Large-size nanoparticles can accumulate in the endoplasmic
reticulum system. Further, the immunogenicity of nanoparticles can cause autoimmunity. Many different types of
nanoparticles have been tested; each may have different side
effects, and some side effects caused by nanoparticles may
be fatal.129 However, overall, the side effects of nanoparticles
are not very well understood at present, and many more
studies are needed.

Conclusion
Metastatic melanoma is still a difficult disease to treat.
The key for improving the treatment efficacy is to have a
better understanding of the pathogenesis of the disease,
early diagnosis and identification of individual molecular
typing, as well as novel and effective drug delivery systems.
Nanotechnology has offered the potential to improve the
diagnosis and treatment of melanoma. It has been demonstrated that nanoparticle-delivered anticancer drugs
concentrate in tumor tissue and thus increase treatment
efficacy and reduce side effects. Nanoparticles have also
been shown to carry imaging agents to detect melanoma
and BRAF mutation. Further studies are needed to avoid
the side effects caused by some nanoparticles so that they
can be applied clinically.
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